{"id":416739,"date":"2021-01-19T08:33:30","date_gmt":"2021-01-19T13:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416739"},"modified":"2021-01-19T08:33:30","modified_gmt":"2021-01-19T13:33:30","slug":"recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/","title":{"rendered":"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, Jan.  19, 2021  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oR-n509tXQoLcapleXztIyLyLsU1p6W_CrWZzXGKg3__sEVbiHLFsPE3R5K7aVL2SAyQ5emgPctZgum_d7OlwjFgvWyzX5zJ0KWuRZsCgu8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>NewMediaWire<\/u><\/a> &#8212; Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.\u00a0 During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy\u2122 to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions.\u00a0 Mr. Joyce also reviews the Company\u2019s 2021 clinical initiatives, the competitive landscape, public market comparables and the experience of the Sigyn team in developing first-in-industry therapies.<\/p>\n<p>The interview can be accessed in its entirety at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0WHiGdl3ydznz1jGvWxq7nwAvZgoEVZXQVJSZF3OgkJWOyI_KVdj4uzpMHoARhr00GoyusplXhT2MmmhFiMNyw9pi3sm7DlShvHWXVLMx6E6ZSobHr2GyxgtZ8vyn15CxHopMqRnJHu8ib6C0-3XQjpp1ZT0La6ylUud0G-UezkP9tSMluGo93PeIYtdDjqt1icuNyASoua9HYWc3IMqw9vbvmz_6IcfZd25etjH-gXySdPLPO3IGy-IsIlob5S3\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/wallstreetanalyzer.com\/2021\/01\/18\/sigyn-therapeutics-inc-otcmarkets-sigy\/<\/a><\/p>\n<p>About Sigyn Therapeutics<\/p>\n<p>Sigyn Therapeutics\u2122 is a medical technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. \u00a0Our mission is to save lives.<\/p>\n<p>Sigyn Therapy\u2122 is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.<\/p>\n<p>To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com.<\/p>\n<p>Cautionary Note Regarding Forward-Looking Statements<\/p>\n<p>This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (\u201cSigyn\u201d) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words \u201ccould,\u201d \u201cwill,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201canticipate,\u201d \u201capproximate,\u201d \u201cexpect,\u201d \u201cpotential,\u201d or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn\u2019s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn\u2019s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn\u2019s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn\u2019s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity\u2019s ability to up-list to a national securities exchange, (viii) risks related to the combined entity\u2019s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management\u2019s attention from Sigyn\u2019s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn\u2019s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p>Contact Sigyn Therapeutics, Inc.<\/p>\n<p align=\"start\">Jim Joyce<\/p>\n<p align=\"start\">Chairman, CEO<\/p>\n<p align=\"start\">(619) 368-2000<\/p>\n<p align=\"start\">jj@sigyntherapeutics.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/500ba37d-ab79-4e19-a0a2-f1afa99d714f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.\u00a0 During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy\u2122 to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions.\u00a0 Mr. Joyce also reviews the Company\u2019s 2021 clinical initiatives, the competitive landscape, public market comparables and the experience of the Sigyn team in developing first-in-industry therapies. The interview can be accessed in its entirety at:\u00a0https:\/\/wallstreetanalyzer.com\/2021\/01\/18\/sigyn-therapeutics-inc-otcmarkets-sigy\/ About Sigyn Therapeutics Sigyn Therapeutics\u2122 is a medical technology company headquartered in San Diego, California USA. Our focus is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416739","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.\u00a0 During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy\u2122 to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions.\u00a0 Mr. Joyce also reviews the Company\u2019s 2021 clinical initiatives, the competitive landscape, public market comparables and the experience of the Sigyn team in developing first-in-industry therapies. The interview can be accessed in its entirety at:\u00a0https:\/\/wallstreetanalyzer.com\/2021\/01\/18\/sigyn-therapeutics-inc-otcmarkets-sigy\/ About Sigyn Therapeutics Sigyn Therapeutics\u2122 is a medical technology company headquartered in San Diego, California USA. Our focus is &hellip; Continue reading &quot;Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T13:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview\",\"datePublished\":\"2021-01-19T13:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/\"},\"wordCount\":800,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/\",\"name\":\"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==\",\"datePublished\":\"2021-01-19T13:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/","og_locale":"en_US","og_type":"article","og_title":"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview - Market Newsdesk","og_description":"SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.\u00a0 During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy\u2122 to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions.\u00a0 Mr. Joyce also reviews the Company\u2019s 2021 clinical initiatives, the competitive landscape, public market comparables and the experience of the Sigyn team in developing first-in-industry therapies. The interview can be accessed in its entirety at:\u00a0https:\/\/wallstreetanalyzer.com\/2021\/01\/18\/sigyn-therapeutics-inc-otcmarkets-sigy\/ About Sigyn Therapeutics Sigyn Therapeutics\u2122 is a medical technology company headquartered in San Diego, California USA. Our focus is &hellip; Continue reading \"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T13:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview","datePublished":"2021-01-19T13:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/"},"wordCount":800,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/","name":"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==","datePublished":"2021-01-19T13:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzY3NyMzOTM0MjQ3IzUwMDAzMjA5OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recent-milestone-achievements-of-sigyn-therapeutics-discussed-during-ceo-interview\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416739"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416739\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}